Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.

导出 LinkOut

翻译打印收藏纠错

作者： Timo,Marttila ^[1] ; Riikka,Järvinen ^[2] ; Tapani,Liukkonen ^[3] ; Erkki,Rintala ^[2] ; Peter,Boström ^[4] ; Marjo,Seppänen ^[5] ; Teuvo,Tammela ^[6] ; Pekka,Hellström ^[7] ; Sirpa,Aaltomaa ^[8] ; Markku,Leskinen ^[9] ; Mika,Raitanen ^[9] ; Eero,Kaasinen ^[10] ; FinnBladder Group

作者单位： Department of Urology, Seinäjoki Central Hospital, Seinäjoki, Finland. Electronic address: timo.marttila@epshp.fi. ^[1] Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. ^[2] Department of Surgery, Mikkeli Central Hospital, Mikkeli, Finland. ^[3] Department of Urology, Turku University Hospital, Turku, Finland. ^[4] Department of Surgery, Satakunta Central Hospital, Pori, Finland. ^[5] Department of Urology, Tampere University Hospital, Tampere, Finland. ^[6] Department of Urology, Oulu University Hospital, Oulu, Finland. ^[7] Department of Urology, Kuopio University Hospital, Kuopio, Finland. ^[8] Department of Urology, Seinäjoki Central Hospital, Seinäjoki, Finland. ^[9] Department of Surgery, Hyvinkää Hospital and Helsinki University Hospital, Hyvinkää, Finland. ^[10]

关键词 Bacillus Calmette-Guérin Epirubicin Instillation therapy Interferon α-2b Mitomycin C Recurrent non–muscle-invasive bladder cancer SWOG